enadenotucirev
Biologicalexperimental
Enadenotucirev is an investigational oncolytic virus that is in clinical trials for various cancers. — Wikipedia
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT02028442)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEnadenotucirev ↗
- ChEMBLCHEMBL4297746 ↗
Also known as
- colo-ad1
- enadenotucirev
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03916510 | Phase 1 | Jun 30, 2019 | Cancer Research UK, PsiOxus Therapeutics Ltd, University of Oxford |
| NCT02636036 | Phase 1 | Jan 1, 2016 | Bristol-Myers Squibb, INC Research, PsiOxus Therapeutics Ltd |
| NCT02028117 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2014 | PsiOxus Therapeutics Ltd |
| NCT02053220 | Phase 1 | Jun 1, 2013 | PsiOxus Therapeutics Ltd |
| NCT02028442 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2012 | PsiOxus Therapeutics Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PsiOxus Therapeutics Ltd | For profit | 5 | 4 | 2 | 2012 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2016 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2019 |
| INC Research | For profit | 1 | 0 | 1 | 2016 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2019 |
5 organizations
Page 1 / 1